JP2013508406A5 - - Google Patents

Download PDF

Info

Publication number
JP2013508406A5
JP2013508406A5 JP2012535392A JP2012535392A JP2013508406A5 JP 2013508406 A5 JP2013508406 A5 JP 2013508406A5 JP 2012535392 A JP2012535392 A JP 2012535392A JP 2012535392 A JP2012535392 A JP 2012535392A JP 2013508406 A5 JP2013508406 A5 JP 2013508406A5
Authority
JP
Japan
Prior art keywords
compound
hcl
solvent
base
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012535392A
Other languages
English (en)
Japanese (ja)
Other versions
JP5789611B2 (ja
JP2013508406A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/053628 external-priority patent/WO2011050215A1/en
Publication of JP2013508406A publication Critical patent/JP2013508406A/ja
Publication of JP2013508406A5 publication Critical patent/JP2013508406A5/ja
Application granted granted Critical
Publication of JP5789611B2 publication Critical patent/JP5789611B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012535392A 2009-10-23 2010-10-21 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス Expired - Fee Related JP5789611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25463409P 2009-10-23 2009-10-23
US61/254,634 2009-10-23
PCT/US2010/053628 WO2011050215A1 (en) 2009-10-23 2010-10-21 Process for preparing modulators of cystic fibrosis transmembrane conductance regulator

Publications (3)

Publication Number Publication Date
JP2013508406A JP2013508406A (ja) 2013-03-07
JP2013508406A5 true JP2013508406A5 (enExample) 2013-11-21
JP5789611B2 JP5789611B2 (ja) 2015-10-07

Family

ID=43530872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012535392A Expired - Fee Related JP5789611B2 (ja) 2009-10-23 2010-10-21 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス

Country Status (16)

Country Link
US (4) US8344147B2 (enExample)
EP (1) EP2491018A1 (enExample)
JP (1) JP5789611B2 (enExample)
KR (1) KR20120104554A (enExample)
CN (1) CN102648182A (enExample)
AR (1) AR080065A1 (enExample)
AU (1) AU2010310612A1 (enExample)
BR (1) BR112012009583A2 (enExample)
CA (1) CA2778492A1 (enExample)
IL (1) IL219326A0 (enExample)
MX (1) MX2012004790A (enExample)
NZ (1) NZ600172A (enExample)
RU (1) RU2553989C2 (enExample)
TW (1) TWI475023B (enExample)
WO (1) WO2011050215A1 (enExample)
ZA (1) ZA201202915B (enExample)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1898221A (zh) 2003-09-06 2007-01-17 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白的调控剂
US7977322B2 (en) 2004-08-20 2011-07-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
HUE032540T2 (en) 2004-06-24 2017-09-28 Vertex Pharma Modulators of ATP-binding cassette transporters
ATE512145T1 (de) 2005-08-11 2011-06-15 Vertex Pharma Modulatoren des cystic fibrosis transmembrane conductance regulators
EP2395002B1 (en) 2005-11-08 2014-06-18 Vertex Pharmaceuticals Inc. Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101395147B (zh) 2005-12-28 2013-05-29 弗特克斯药品有限公司 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物
PT2674428T (pt) 2006-04-07 2016-07-14 Vertex Pharma Modeladores de transportadores de cassetes de ligação de atp
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
NZ581259A (en) 2007-05-09 2012-07-27 Vertex Pharma Modulators of cystic fibrosis transmembrane conductance regulator
HUE028426T2 (en) 2007-08-24 2016-12-28 Vertex Pharma Isothiazolopyridinones for (inter alia) treating cystic fibrosis
ES2556080T3 (es) 2007-11-16 2016-01-12 Vertex Pharmaceuticals Incorporated Moduladores de isoquinolina de transportadores de casete de unión a ATP
UA102534C2 (xx) 2007-12-07 2013-07-25 Вертекс Фармасьютикалз Инкорпорейтед ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ)
UA95199C2 (en) * 2007-12-07 2011-07-11 Вертекс Фармасьютикалз Инкорпорейтед Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
LT2639223T (lt) 2007-12-07 2017-06-26 Vertex Pharmaceuticals Incorporated Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas
US20100036130A1 (en) 2007-12-07 2010-02-11 Vertex Pharmaceuticals Incorporated Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
NZ602030A (en) 2008-02-28 2014-02-28 Vertex Pharma Heteroaryl derivatives as cftr modulators
NZ616097A (en) 2008-03-31 2015-04-24 Vertex Pharma Pyridyl derivatives as cftr modulators
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX2011003249A (es) * 2008-09-29 2011-05-19 Vertex Pharma Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co.
AR074060A1 (es) 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
NZ592504A (en) * 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
EP2821400B1 (en) 2009-03-20 2017-09-27 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
KR20120083416A (ko) * 2009-09-17 2012-07-25 버텍스 파마슈티칼스 인코포레이티드 아자비시클릭 화합물의 제조 방법
US8389727B2 (en) * 2009-10-23 2013-03-05 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN102917692A (zh) 2010-04-07 2013-02-06 弗特克斯药品有限公司 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法
NZ602795A (en) 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2797118C (en) 2010-04-22 2021-03-30 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8404849B2 (en) * 2010-05-20 2013-03-26 Vertex Pharmaceuticals Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
US8563593B2 (en) 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
AU2012335714B2 (en) 2011-11-08 2017-04-13 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
RU2692779C2 (ru) 2012-02-27 2019-06-27 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
US8674108B2 (en) 2012-04-20 2014-03-18 Vertex Pharmaceuticals Incorporated Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013290444B2 (en) 2012-07-16 2018-04-26 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof
BR112016010403A2 (pt) 2013-11-12 2017-08-08 Vertex Pharma Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr
CA2944140C (en) 2014-04-15 2022-10-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
RU2749213C2 (ru) 2014-10-07 2021-06-07 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе
US10302602B2 (en) 2014-11-18 2019-05-28 Vertex Pharmaceuticals Incorporated Process of conducting high throughput testing high performance liquid chromatography
JP7158717B2 (ja) * 2017-11-22 2022-10-24 国立大学法人九州工業大学 求電子的アジド化剤又はジアゾ化剤
CN109369798B (zh) * 2018-12-25 2020-09-15 苏州天马医药集团天吉生物制药有限公司 一种合成索玛鲁肽的方法
CR20230120A (es) 2020-08-07 2023-09-01 Vertex Pharma Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en) 2020-11-18 2025-06-10 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
SK286420B6 (sk) * 1997-09-15 2008-09-05 The Procter & Gamble Company Zlúčenina so štruktúrou chinolónu, farmaceutický prostriedok s jej obsahom a jej použitie
NZ505362A (en) * 1997-12-22 2004-12-24 Upjohn Co 4-hydroxyquinoline-3-carboxamides and -hydrazides useful as antiviral agents
HUE032540T2 (en) 2004-06-24 2017-09-28 Vertex Pharma Modulators of ATP-binding cassette transporters
AU2008298545B2 (en) * 2007-09-14 2013-12-12 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL2444120T3 (pl) 2007-12-10 2018-02-28 Novartis Ag Spirocyklicze analogi amiloridu jako blokery ENac
NZ592504A (en) * 2008-10-23 2013-04-26 Vertex Pharma Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
AR074060A1 (es) * 2008-10-23 2010-12-22 Vertex Pharma Moduladores del regulador de conductancia transmembrana de la fibrosis quistica
US8389727B2 (en) * 2009-10-23 2013-03-05 Vertex Pharmaceuticals Incorporated Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide

Similar Documents

Publication Publication Date Title
JP2013508406A5 (enExample)
RU2012121160A (ru) Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза
TWI475992B (zh) 製備4-{4-[({[4-氯-3-(三氯甲基)-苯基]胺基}羰基)胺基]-3-氟苯氧基}-n-甲基吡啶-2-甲醯胺、其鹽及單水合物之方法
JP2010505926A5 (enExample)
CN116987112B (zh) 制备氨基嘧啶衍生物的改善方法
CN114805308A (zh) 一种合成氨基嘧啶类fak抑制剂化合物的方法
CN108623567A (zh) 奥斯替尼的制备方法
CN105085276A (zh) 艾曲波帕中间体及其制备方法和应用
CN107089984B (zh) 一种替卡格雷的合成方法
WO2011090122A1 (ja) 2-アミノ-4-トリフルオロメチルピリジン類の製造方法
CN101982463B (zh) 芳基5-吡唑啉酮的制备方法
Connolly et al. An eco-efficient pilot plant scale synthesis of two 5-substituted-6, 7-dimethoxy-1-H-quinazoline-2, 4-diones
JP2008545782A5 (enExample)
CN106831768A (zh) 一种2,6‑二氯吡啶[3,4‑b]吡嗪的合成方法
CN108329236B (zh) 一种恩杂鲁胺中间体的制备方法
TW201111350A (en) Process for preparing 2-arylamino or heteroarylamino substituted benzimidazole compounds
CN114716369A (zh) 有害生物防除剂的最佳制造方法
CN108794413A (zh) 一种1,2,4-三氮唑-3-甲酰胺的合成方法
JP6709509B2 (ja) 窒素含有ペンタフルオロスルファニルベンゼン化合物の製造方法
CN105481779A (zh) 抗癌药物Rociletinib及其中间体制备
Jinyu et al. Study on N-Alkylation Reactions of Trifluoromethylated Acylhydrazones
JP3448635B2 (ja) スルフェンアミド化合物及びその製造方法
JP2008518910A5 (enExample)
CN101624323A (zh) 一种伯胺和仲胺类化合物的制备方法
Laskina et al. Synthesis of new quinoxaline derivatives